Lundbeckfond Invest A/S - Nov 7, 2023 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: 10%+ Owner
Signature: /s/ Christian E. Elling, Managing Partner and /s/ Lene Skole, Chief Executive Officer
Stock symbol: LXEO
Transactions as of: Nov 7, 2023
Transactions value $: $2,499,992
Form type: 4
Date filed: 11/9/2023, 08:33 PM
Previous filing: Nov 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXEO	Common Stock	Conversion of derivative security		+1.32M			1.32M	Nov 7, 2023	Direct	F1
transaction	LXEO	Common Stock	Conversion of derivative security		+287K	+21.73%		1.61M	Nov 7, 2023	Direct	F2
transaction	LXEO	Common Stock	Purchase	$2.5M	+227K	+14.13%	$11.00^*	1.84M	Nov 7, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXEO	Series A convertible preferred stock	Conversion of derivative security		-14M	-100%		0	Nov 7, 2023	Common Stock	1.32M		Direct	F1
transaction	LXEO	Series B convertible preferred stock	Conversion of derivative security		-2.62M	-100%		0	Nov 7, 2023	Common Stock	287K		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Lundbeckfond Invest A/S is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
F2	Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Content

Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.